Coronavirus: No plans regarding ban on exports of active pharmaceutical ingredients, says Indian Pharmaceutical Alliance

“The biggest hit will be taken up by cephalosporin or Penicillin G manufacturer because almost most of the companies in India have shut down their shops and they source it from China because they are cheapest there,” Surajit Pal, pharma analyst at Prabhudas Lilladher, said.

Reacting to the news, Vijay Garg, joint MD of IOL Chemicals, said, “If the export ban is there then problems definitely will come but as far as IOL is concerned, we are majorly into pain management. Our flagship product is Ibuprofen. So we are very minimal dependent on China and moreover the product which we are importing from China is not in the epicentre of the outbreak. We are covered for six months plus we have an alternative. Definitely the problem will come only in antibiotics or in diabetics where the dependence is much more."